{"analyses":[{"ciLowerLimit":"0.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.70","groupDescription":"Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0051","paramType":"Hazard Ratio (HR)","paramValue":"0.23","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG000","lowerLimit":"4.67","upperLimit":"NA","value":"6.28"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"DOR was defined as the time interval from the date of first occurrence of a documented objective response (CR or PR, whichever status is recorded first) until the first date that disease progression (PD) or death was documented, whichever occurs first as determined by the IRF according to RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \\>/= 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEDIAN","populationDescription":"The analysis population included Global participants with a confirmed response (CR or PR).","reportingStatus":"POSTED","timeFrame":"Randomization up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"Duration of Response by IRF-Assessment (DOR-IRF) Per RECIST v1.1 in the Global Population","type":"SECONDARY","unitOfMeasure":"months"}